Teva Confirms Efficacy and Safety of AJOVY(TM) (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Stockwatch,
AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy…